Zadaxin thymalfasin: Pilot trial data

Top-line data from an ongoing, open-label, Italian pilot trial in 120 patients with ESRD on hemodialysis showed that Focetria influenza vaccine plus 3.2 or 6.4 mg Zadaxin met the primary endpoint of a significantly greater proportion of patients achieving seroconversion at 21 days post-vaccination vs. Focetria alone (89% and 88% vs. 56%, respectively, p<0.01 for both). Patients received Focetria plus 3.2 or 6.4 mg Zadaxin given 7 days prior to vaccination and on the day of vaccination or Focetria alone. ...